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Background/aim: Oxaliplatin is an effective and widely used chemotherapeutic agent in the treatment of many solid tumors. The most
common side effects are peripheral neuropathy, gastrointestinal toxicity, and neutropenia. There have been some case reports about
ototoxicity with oxaliplatin, but no clinical trials. In this trial, we explored whether or not oxaliplatin has ototoxic effects.
Materials and methods: A total of 18 patients, 14 with colorectal cancer and 4 with pancreatic cancer, were included in this study. Four
patients (22%) were treated with a capecitabine and oxaliplatin (CapeOx) regimen, and 14 patients (78%) were treated with fluorouracil,
leucovorin, and oxaliplatin (FOLFOX-6). Patients’ pretreatment and posttreatment hearing levels were assessed with high-frequency
audiometry and otoacoustic emission tests.
Results: The median time between the first and the last oxaliplatin doses was 3.2 months (range: 2–7 months). There was no hearing
loss in tests conducted for both ears of patients at frequencies of 500, 1000, 2000, 4000, 6000, 8000, 12,000, and 16,000 Hz. There was no
difference between the pretreatment and posttreatment otoacoustic emission tests.
Conclusion: Oxaliplatin is a reliable agent in terms of ototoxicity.
Key words: Cancer, ototoxicity, oxaliplatin

1. Introduction
Oxaliplatin is a new platinum compound agent used in the
treatment of many cancers, especially colorectal cancer
(CRC). It gained European approval in 1996 and Food
and Drug Administration approval in 2002. As a single
agent, oxaliplatin shows modest activity in CRC, but when
combined with fluorouracil and leucovorin, it has diseasefree survival (DFS) benefits in stage II and III CRC patients.
In a study by Andre et al., DFS rates were 78.2% in patients
treated with fluorouracil plus leucovorin and oxaliplatin
and 72.9% with fluorouracil and leucovorin alone (P =
0.002) (1). The DFS difference was statistically significant
only in the stage III group. The National Surgical Adjuvant
Breast and Bowel Project’s C-07 trial further strengthened
the role of oxaliplatin in the adjuvant setting. Its role in
the metastatic setting has also been demonstrated in many
trials, with both fluorouracil and capecitabine (2).
Oxaliplatin is also used (unlabeled) in the treatment
of esophageal, gastric, advanced hepatobiliary, advanced
ovarian, pancreatic, and refractory testicular cancers and
refractory non-Hodgkin lymphoma (3).
* Correspondence: salimyucekbb@hotmail.com
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Unfortunately, although oxaliplatin has a wide
therapeutic range, it may cause serious side effects, the
most common of which are fatigue, nausea, vomiting,
diarrhea, constipation, and neuropathy (4). Neuropathy
may be acute and persistent, and it may be dose-limiting
(5). Oxaliplatin-induced neuropathy is generally seen in
the peripheral nervous system. Although there are a few
relevant case reports, there has not yet been a clinical trial
on oxaliplatin-related ototoxicity (ORO), which is what we
have aimed to provide here.
2. Materials and methods
The patients included in this study were diagnosed and
treated with oxaliplatin-based chemotherapy regimens at
the Cumhuriyet University Faculty of Medicine’s Medical
Oncology Department. Institutional review board
approval was obtained for the study.
The patients’ ages, sex, primary tumor types,
tumor stages, chemotherapy regimens, tumor markers,
hematological parameters, and liver and kidney
function tests were recorded. Before and after 6 cycles of
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chemotherapy application, all patients’ hearing evaluations
were completed using pure-tone and high-frequency
audiometry. Otoacoustic emission tests were also given to
all patients.
The patients were treated with oxaliplatin-based
regimens,
either
fluorouracil/leucovorin/oxaliplatin
(FOLFOX) or capecitabine/oxaliplatin (CapeOx).
Tympanograms were done with the Impedance
Audiometer AZ 26. Pure-tone audiometry was conducted
with the Clinical Audiometer AC 40 and TDH-39P
Telephonic HB-7 earphones, and high-frequency
audiometry analysis was completed with the AC 40
Interacoustic Clinical Audiometer and Koss digital
earphones R/80. Hearing evaluations were done in
accordance with the American National Standard S3-1.
Hearing levels above 26 dB were accepted as pathological.
Data from the study were loaded into SPSS 14.5 and
evaluated using the Mann–Whitney U test, analysis of
variance, Bonferroni test, and chi-square test. The level of
statistical significance was set at 0.05.

Table 1. Patients’ characteristics.

3. Results
A total of 18 patients (9 males, 9 females) were included
in this study. Fourteen (77.7%) of them had CRC and 4
(22.2%) had pancreatic cancer (PC). Eleven of the 14
CRC patients received oxaliplatin in the adjuvant setting.
The other 3 CRC patients and all of the PC patients were
metastatic (Table 1). Fourteen (77.7%) patients received
the FOLFOX treatment, and 4 patients (22.2%) received
CapeOx.

The median time between the first and last oxaliplatin
administration was 105 days (range: 56–212 days). The
hearing levels of all patients were assessed with hearing tests
at 500, 1000, 2000, 4000, 6000, 8000, 12,000, and 16,000
Hz before and after chemotherapy (Table 2). There was no
statistically significant difference between pretreatment
and posttreatment hearing levels. Pretreatment and
posttreatment otoacoustic emission testing was given to
all patients and no pathologies were detected.

Age, years

58 (25–76)

Sex
Male

(n)

9 (50%)

Female

(n)

9 (50%)

Colorectal cancer

(n)

14 (77.7%)

Pancreatic cancer

(n)

4 (22.2%)

FOLFOX

(n)

14 (77.7%)

CapeOx

(n)

4 (22.2%)

Primary cancer

Chemotherapy regimen

Median oxaliplatin dosage (mg)

672 (290–1200)

Table 2. Hearing levels before and after chemotherapy.

Frequency (Hz)

Right ear
BC (dB)

AC (dB)

500

19.7 ± 10.7

1000

P

Left ear
BC (dB)

AC (dB)

19.1 ± 11.7

17.2 ± 10.6

18.8 ± 12.1

15.5 ± 9.5

16.1 ± 10.3

15.2 ± 9.4

18.3 ± 13.3

2000

16.6 ± 13.1

17.7 ± 14.2

18.8 ± 12.5

21.9 ± 18.8

4000

26.9 ± 16.8

29.1 ± 17.7

33.0 ± 19.2

36.3 ± 22.6

6000

33.2 ± 24.5

36.1 ± 24.6

38.6 ± 25.8

41.3 ± 26.2

8000

39.7 ± 25.8

43.0 ± 24.7

41.9 ± 27.2

45.5 ± 25.7

12,000

51.9 ± 26.3

53.3 ± 27.9

54.1 ± 23.4

55.2 ± 25.2

16,000

51.3 ± 19.3

51.3 ± 21.2

51.9 ± 17.4

51.3 ± 18.3

>0.05

P

>0.05

BC: Before chemotherapy, AC: after chemotherapy.
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4. Discussion
This study assessed and analyzed the audiological functions
of 18 patients undergoing chemotherapy with oxaliplatin.
Ototoxicity due to platinum-containing agents, especially
cisplatin and carboplatin, has been reported in many
publications. These agents may damage the cochleae and
may cause vertigo, tinnitus, and hearing loss. Ototoxicity
due to cisplatin has been reported in 10%–70% of adults
(6,7). In a study by Reddel et al. (8), ototoxicity was detected
in 72% of adult patients treated with cisplatin. Cisplatin
ototoxicity in adults and children may lead to hearing
loss, starting as sensorineural tinnitus. Hearing loss begins
at high frequencies and then progresses towards lower
frequencies, which are crucial for hearing speech (9).
Dutta et al. investigated the audiological functions
of patients who had been treated with cisplatin-based
regimens. They found that bilateral sensorineural hearing
loss had developed in 15% of patients. This hearing loss was
especially prominent at 4000 Hz and higher frequencies
(10).
Carboplatin is an ototoxic platinum analog. Although
carboplatin has been found to be ototoxic, its toxicity is
significant, especially in myeloablative doses. Kennedy et
al. concluded that carboplatin is not ototoxic at standard
doses and that routine audiometric surveillance need not
be recommended (11).

Ototoxicity due to platinum compounds has also been
reported in pediatric patients. The incidence of ototoxicity
in this population is 50%–80% with cisplatin and 1%–35%
with carboplatin (12,13).
The XELOX regimen was associated with a higher
frequency and severity of diarrhea, thrombocytopenia,
and hand-foot syndrome, whereas FOLFOX-4 was
associated with more grade 3–4 neutropenia. However,
since the efficacies of the different treatment regimens are
equivalent in metastatic gastrointestinal tumors (14,15),
the use of oral chemotherapeutic regimens is certainly
more comfortable for outpatients and thus positively
influences patient compliance.
In a study by Hellberg et al., oxaliplatin was found
to have minimal ototoxicity, and they attributed this to
limited cochlear uptake of oxaliplatin (16).
In our study, we did not find ototoxicity with oxaliplatin
in either high-frequency audiometry or otoacoustic
emission testing. The cochlear uptake of oxaliplatin is not
as high as with cisplatin and carboplatin. Thus, ototoxicity
is rare with oxaliplatin usage.
Oxaliplatin is one of the most-used agents for colorectal,
pancreatic, and gastric cancers, and studies have also
shown that oxaliplatin is active in many tumors. Its most
common side effects are nausea, diarrhea, myelotoxicity,
and peripheral neuropathy. As far as we know, this is the
biggest trial of ORO in the literature, and we can say that
oxaliplatin is a safe agent in terms of ototoxicity.
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